Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Portfolio Pulse from
Lexicon Pharmaceuticals has completed enrollment in its Phase 2B PROGRESS study of LX9211 for treating diabetic peripheral neuropathic pain, exceeding its target by 20% and finishing ahead of schedule.
November 26, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lexicon Pharmaceuticals has successfully completed enrollment in its Phase 2B study for LX9211, a treatment for diabetic peripheral neuropathic pain, with enrollment exceeding the target by 20% and finishing ahead of schedule.
The completion of enrollment in the Phase 2B study for LX9211, especially with a 20% excess in target enrollment and ahead of schedule, indicates strong interest and potential for the drug. This positive development is likely to boost investor confidence and positively impact Lexicon's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90